808 results on '"Acosta, Edward P."'
Search Results
52. Pharmacodynamics of Antiretroviral Agents
53. Effect of CYP2B6, ABCB1, and CYP3A5 Polymorphisms on Efavirenz Pharmacokinetics and Treatment Response: An AIDS Clinical Trials Group Study
54. Oseltamivir Dosing for Influenza Infection in Premature Neonates
55. Associations between CYP2B6 Polymorphisms and Pharmacokinetics after a Single Dose of Nevirapine or Efavirenz in African Americans
56. Perinatal pharmacokinetics of azithromycin for cesarean prophylaxis
57. Efavirenz-Based Regimens in Treatment-Naive Patients with a Range of Pretreatment HIV-1 RNA Levels and CD4 Cell Counts
58. Pharmacokinetic and Pharmacodynamic Assessment of Oral Valgancidovir in the Treatment of Symptomatic Congenital Cytomegalovirus Disease
59. Preexisting Resistance to Nonnucleoside Reverse-Transcriptase Inhibitors Predicts Virologic Failure of an Efavirenz-Based Regimen in Treatment-Naive HIV-1-Infected Subjects
60. Integrated Population Pharmacokinetic/Viral Dynamic Modelling of Lopinavir/Ritonavir in HIV-1 Treatment-Naïve Patients
61. Pharmacokinetics of Once-Daily Darunavir/Ritonavir With and Without Etravirine in Human Immunodeficiency Virus-Infected Children, Adolescents, and Young Adults
62. Cerebrospinal Fluid Concentrations of Tenofovir and Emtricitabine in the Setting of HIV-1 Protease Inhibitor-Based Regimens
63. A Randomized, Double-Blind, Placebo-Controlled Trial of Pleconaril for the Treatment of Neonates With Enterovirus Sepsis
64. Weighted Phenotypic Susceptibility Scores Are Predictive of the HIV-1 RNA Response in Protease Inhibitor-Experienced HIV-1-Infected Subjects
65. Pharmacokinetics and 48-Week Safety and Efficacy of Raltegravir for Oral Suspension in Human Immunodeficiency Virus Type-1-Infected Children 4 Weeks to 2 Years of Age
66. Sex-Based Differences in Saquinavir Pharmacology and Virologic Response in AIDS Clinical Trials Group Study 359
67. The Pharmacokinetics of Amprenavir, Zidovudine, and Lamivudine in the Genital Tracts of Men Infected with Human Immunodeficiency Virus Type 1 (AIDS Clinical Trials Group Study 850)
68. Population pharmacokinetic analysis of raltegravir pediatric formulations in HIV-infected children 4 weeks to 18 years of age
69. Valganciclovir for Congenital Cytomegalovirus
70. Impact of protease inhibitors on intracellular concentration of tenofovir-diphosphate among HIV-1 infected patients
71. Valganciclovir for Symptomatic Congenital Cytomegalovirus Disease
72. Additional file 1 of An open-label, pilot study of veliparib and lapatinib in patients with metastatic, triple-negative breast cancer
73. Additional file 3 of An open-label, pilot study of veliparib and lapatinib in patients with metastatic, triple-negative breast cancer
74. Disposition of Zidovudine in Obese Pregnant Women with Human Immunodeficiency Virus Type 1 Infection
75. A sensitive HPLC–MS–MS method for the determination of raltegravir in human plasma
76. Variable cellular ivacaftor concentrations in people with cystic fibrosis on modulator therapy
77. Effect of Protein Binding on Unbound Atazanavir and Darunavir Cerebrospinal Fluid Concentrations
78. Secondary metabolism pathway polymorphisms and plasma efavirenz concentrations in HIV-infected adults with CYP2B6 slow metabolizer genotypes
79. Pharmacologic aspects of new antiretroviral drugs
80. Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs
81. Abstract PS10-30: An open label, pilot study of veliparib and lapatinib in patients with metastatic, triple negative breast cancer
82. Pharmacokinetics, Safety, Tolerability and Antiviral Activity of Dolutegravir Dispersible Tablets in Infants and Children with HIV-1: Results of the IMPAACT P1093 Study, a Phase I/II Open-Label Trial
83. Improving Data Reliability Using a Non-Compliance Detection Method versus Using Pharmacokinetic Criteria
84. Pharmacodynamics of Antiretroviral Agents in HIV-1 Infected Patients: Using Viral Dynamic Models that Incorporate Drug Susceptibility and Adherence
85. Tipranavir: A Novel Nonpeptidic Protease Inhibitor of HIV
86. Persistence of neviparine in breast milk after discontinuation of treatment
87. Lopinavir/ritonavir pharmacokinetic profile: impact of sex and other covariates following a change from twice-daily to once-daily therapy
88. Pharmacokinetics of saquinavir with atazanavir of low-dose ritonavir administered once daily (ASPIRE I) or twice daily (ASPIRE II) in seronegative volunteers
89. PHARMACOKINETICS AND SAFETY OF RALTEGRAVIR IN 2 to 12 YEAR OLD CHILDREN WITH HIV RECEIVING RIFAMPICIN FOR TUBERCULOSIS
90. Three- versus four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: A randomized controlled trial
91. Clinical pharmacodynamics of HIV-1 protease inhibitors: use of inhibitory quotients to optimise pharmacotherapy
92. Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group study
93. Pharmacokinetic Enhancement of Protease Inhibitor Therapy
94. Four measures of antiretroviral medication adherence and virologic response in AIDS clinical trials group study 359
95. Modeling long-term HIV dynamics and antiretroviral response: Effects of drug potency, pharmacokinetics, adherence, and drug resistance
96. A Phase 1/2 Randomized, Placebo-Controlled Trial of Romidespin in Persons With HIV-1 on Suppressive Antiretroviral Therapy
97. Pharmacokinetics and safety of maraviroc in neonates
98. Toward Consensus on Correct Interpretation of Protein Binding in Plasma and Other Biological Matrices for COVID‐19 Therapeutic Development
99. Comparison of two indinavir/ritonavir in the treatment of HIV-infected individuals
100. Detection of Nevirapine in plasma using thin-layer chromatography
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.